When Molecules Aren’t Enough | Ep. 731

Evolving Biotech Strategy with Adaptive Macro Hedging

Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we unpack how to protect a high-risk biotech portfolio when macro volatility takes the wheel. Even the best science can get crushed in a funding freeze, a yield spike, or a sudden liquidity drain, so we explored how to build a smart, adaptable macro hedge using real 2024–2025 return data. We tested what worked (GLD, HYG, VIX calls), what didn’t (TBF, UUP), and how to create a simple rule-based overlay that trims drawdowns without dulling upside. If you’re managing conviction trades into binary catalysts, this is the risk shield you didn’t know you needed, until Powell speaks or CPI prints.

We are now publishing 7x per week according to the following cadence:

• Mondays: Stocks

• Tuesdays: Biotech

• Wednesdays: Podcast

• Thursdays: Markets

• Fridays: News

• Saturdays: Podcast

• Sundays: Strategy

We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.

SUBSCRIBE TO PODCAST HERE:

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

Enough shilling for the day, lots to cover this week, let's get started!

Introduction

In public biotech investing, risk is often framed in terms of science, mechanism of action, clinical design, manufacturing, competition. Investors build portfolios around catalytic events, model risk-adjusted NPVs, and tune exposure to data readouts. And yet, the greatest sources of portfolio pain often have little to do with biology. They come from somewhere else entirely.

Inflation reports.

Central bank policy.

Treasury auctions.

Currency shocks.

In recent years, macro has become a primary driver of biotech performance, often more so than trial outcomes.

The volatility of inflation expectations, the cost of capital, and the strength of the dollar are deeply intertwined with liquidity, funding access, and risk-on/risk-off flows. Ignoring macro in biotech strategy today is like ignoring immunogenicity in a gene therapy program: reckless.

Today we walk through how to integrate macro hedging into a biotech portfolio, how to upgrade that hedge based on real-world conditions, and how new tools like Bitcoin can strengthen your portfolio’s immunity to shocks. We’ll examine what worked in 2024, what failed in early 2025, and how a redesigned hedge, anchored in credit, volatility, gold, and now crypto, helped buffer downside without sacrificing upside.

2024: A Macro Hedge That Aged Poorly